Shoaib Safiullah, MD
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.6%), travel and lodging and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Boston Scientific at 54.9% of the total. 2025 is the largest year on record at $4,035, more than ten times the $263 reported in 2019.
Across 243 payments — averaging $59.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$8K
- Teleflex LLC$1K
- Uromedica, Incorporated$1K
- Medtronic$469
- AbbVie$342
- Medical Device Business Services, Inc.$305
- plus $3K from 31 others
What the payments were for
- Travel & lodging$6,31344%
- Food & beverage$7,58453%
- Education$5214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 81 | $7,916 |
| Teleflex LLC | 15 | $1,052 |
| Uromedica, Incorporated | 2 | $1,016 |
| Medtronic(2 entities) | 9 | $469 |
| AbbVie | 16 | $342 |
| Medical Device Business Services, Inc. | 1 | $305 |
| Astellas Pharma US Inc | 8 | $298 |
| Pfizer | 14 | $291 |
| Sumitomo Pharma America, Inc. | 6 | $288 |
| Procept Biorobotics Corporation | 7 | $278 |
| Calyxo, Inc. | 3 | $220 |
| Ferring Pharmaceuticals Inc. | 11 | $217 |
| Axonics, Inc. | 3 | $185 |
| Bayer | 3 | $175 |
| Antares Pharma, Inc. | 10 | $171 |
| Johnson & Johnson(2 entities) | 8 | $171 |
| Coloplast | 9 | $165 |
| Cook Medical LLC | 2 | $136 |
| Progenics Pharmaceuticals, Inc. | 4 | $98 |
| Tolmar Pharmaceuticals, Inc. | 3 | $75 |
| Novartis | 3 | $70 |
| Baxter Healthcare | 2 | $65 |
| Endo Pharmaceuticals Inc. | 3 | $57 |
| Laborie Medical Technologies Corp. | 3 | $46 |
| Urogen Pharma, Inc. | 2 | $45 |
| Olympus America Inc. | 2 | $39 |
| Endo USA, Inc. | 2 | $38 |
| Blue Earth Diagnostics | 1 | $28 |
| Myriad Genetic Laboratories, Inc. | 2 | $27 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $23 |
| Tempus AI, Inc | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $17 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Myovant Sciences Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS 700 CXR RTE KIT$1,589
- Axonics$1,258
- Lumenis Pulse 120H$1,199
- ProACT$949
- AMS 700$869
- UroLift System$377
- UroLift$350
- Moses 550 DFL$251
- Bulkamid$146
- Xofigo$142
- LithoVue$140
- ORGOVYX$136
- Moses 550 D\F\L$128
- PERCUTANEOUS TRACT KIT$119
- GENERAL ERECTILE DYSFUNCTION$105
How this compares
$14,418 in reported general payments places this provider in the 85th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 14 | $9,789 |
| GemtesaVibegron | 16 | $9,551 |
| Solifenacin Succinate | 79 | $4,722 |
| Estradiol | 23 | $1,741 |
| Tamsulosin Hcl | 138 | $1,428 |
| Finasteride | 45 | $712 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $349 |
| Oxybutynin Chloride | 14 | $166 |
| Ciprofloxacin Hcl | 14 | $71 |
| Cyclobenzaprine Hcl | 16 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $298 | $9,78914 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $288 | $9,55116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 269 urology providers in Arizona.
Other urology in Mesa
- Rahul MehanMesa$277K
- Greggory PeiferMesa$14K
- Harpreet WadhwaMesa$14K
- Daniel GilbertMesa$12K
- John WilliamsMesa$11K
- Kashif AlviMesa$11K
- Raul WebsterMesa$10K
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.